Medications development to treat alcohol dependence: a vision for the next decade

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Addiction Biology

• Publication date

  2012-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1369-1600.2012.00454.xPMID 22458728PMCID PMC3484365
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients.

  2012cited by this paper
• Post-treatment outcomes in a double-blind, randomized trial of sertraline for alcohol dependence.

  2012cited by this paper
• The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and Goals for Assessing Important and Salient Issues for Medications Development in Alcohol Use Disorders

  2012cited by this paper
• A dearth of new meds.

  2011cited by this paper
• How to Revive Breakthrough Innovation in the Pharmaceutical Industry

  2011cited by this paper
• Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.

  2011cited by this paper
• Pharmacogenetic approaches to the treatment of alcohol addiction

  2011cited by this paper
• A Double-Blind, Randomized Trial of Sertraline for Alcohol Dependence: Moderation by Age of Onset and 5-Hydroxytryptamine Transporter-Linked Promoter Region Genotype

  2011cited by this paper
• Medications for Unhealthy Alcohol Use

  2011cited by this paper
• Adoption and Implementation of Medications in Addiction Treatment Programs

  2011cited by this paper
• Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate

  2011cited by this paper
• Reengineering Translational Science: The Time Is Right

  2011cited by this paper
• Personalized medicine can pave the way for the safe use of CB₁ receptor antagonists.

  2011cited by this paper
• Faulty circuits.

  2010cited by this paper
• Biological, clinical, and ethical advances of placebo effects.

  2010cited by this paper
• Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus.

  2010cited by this paper
• REVIEW: Human and laboratory rodent low response to alcohol: is better consilience possible?

  2010cited by this paper
• Neurocircuitry: A Window into the Networks Underlying Neuropsychiatric Disease

  2010cited by this paper
• REVIEW: Reward sensitivity: issues of measurement, and achieving consilience between human and animal phenotypes

  2010cited by this paper
• Substance use disorders: realizing the promise of pharmacogenomics and personalized medicine.

  2010cited by this paper
• Alcohol biomarkers in applied settings: recent advances and future research opportunities.

  2010cited by this paper
• Role of the Human Laboratory in the Development of Medications for Alcohol and Drug Dependence

  2010cited by this paper
• Selective Modulation of Gq/Gs pathways by Naphtho Pyrano Pyrimidines as antagonists of the Neuropeptide S Receptor.

  2010cited by this paper
• Machine Self-awareness

  2010cited by this paper
• REVIEW: Ethanol consumption: how should we measure it? Achieving consilience between human and animal phenotypes

  2010cited by this paper
• How to improve R&D productivity: the pharmaceutical industry's grand challenge

  2010cited by this paper
• Pharmacogenetics of alcohol and alcohol dependence treatment.

  2010cited by this paper
• Is pharma running out of brainy ideas?

  2010cited by this paper
• Individual differences in prefrontal cortex function and the transition from drug use to drug dependence.

  2010cited by this paper
• Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials.

  2010cited by this paper
• Neurocircuitry of Addiction

  2010cited by this paper
• A genetic determinant of the striatal dopamine response to alcohol in men

  2010cited by this paper
• REVIEW: Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked?

  2010cited by this paper
• A Call for Sharing: Adapting Pharmaceutical Research to New Realities

  2009cited by this paper
• The Vote of Acute Medical Inpatients

  2009cited by this paper
• Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders.

  2009cited by this paper
• Neurokinin 1 Receptor Antagonism as a Possible Therapy for Alcoholism

  2009cited by this paper
• Alcoholism: a systems approach from molecular physiology to addictive behavior.

  2009cited by this paper
• Lessons from 60 years of pharmaceutical innovation

  2009cited by this paper
• Development of pharmacotherapies for drug addiction: a Rosetta Stone approach

  2009cited by this paper
• A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers.

  2009cited by this paper
• Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty.

  2009influential reference
• Neuroimaging in geriatric psychiatry

  2009cited by this paper
• Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study.

  2008cited by this paper
• Neurokinin 1 Receptor Antagonism as a Possible Therapy for Alcoholism

  2008cited by this paper
• Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration

  2008cited by this paper
• Network pharmacology: the next paradigm in drug discovery.

  2008cited by this paper
• Prospective study of alcohol consumption in the United States: quantity, frequency, and cause-specific mortality.

  2008cited by this paper
• A prospective study of risk drinking: at risk for what?

  2008cited by this paper
• Different vulnerabilities may contribute to the same phenomena, and some additional interactions (Commentary on Redish, A. D., et al. 'A unified framework for addiction: vulnerabilities in the decision process').

  2008cited by this paper
• Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes.

  2008cited by this paper
• Effect of positive and negative affective stimuli and beverage cues on measures of craving in non treatment-seeking alcoholics

  2008cited by this paper
• Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study.

  2008cited by this paper
• Development of Procedures for Early Screening of Smoking Cessation Medications in Humans

  2008cited by this paper
• Repeated cycles of chronic intermittent ethanol exposure in mice increases voluntary ethanol drinking and ethanol concentrations in the nucleus accumbens

  2008cited by this paper
• Improving acceptance of naltrexone in community addiction treatment centers: a pilot study.

  2008cited by this paper
• Computing motivation: Incentive salience boosts of drug or appetite states

  2008cited by this paper
• Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome

  2008cited by this paper
• Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.

  2008influential reference
• Quantifying the risk for alcohol‐use and alcohol‐attributable health disorders: Present findings and future research needs

  2008cited by this paper
• Gender differences in response to emotional stress: an assessment across subjective, behavioral, and physiological domains and relations to alcohol craving.

  2008cited by this paper
• Selective publication of antidepressant trials and its influence on apparent efficacy.

  2008cited by this paper
• Heavy episodic drinking: determining the predictive utility of five or more drinks.

  2008cited by this paper
• A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Aripiprazole for the Treatment of Alcohol Dependence

  2008cited by this paper
• Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques.

  2007cited by this paper
• Reducing heavy drinking: a public health strategy and a treatment goal?

  2007cited by this paper
• Topiramate for treating alcohol dependence: a randomized controlled trial.

  2007cited by this paper
• Treatment of Depression in Patients With Alcohol or Other Drug Dependence

  2007cited by this paper
• A key role for corticotropin-releasing factor in alcohol dependence.

  2007cited by this paper
• Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.

  2007cited by this paper
• Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.

  2007cited by this paper
• The burden of disease and injury in the United States 1996

  2006cited by this paper
• Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable.

  2006cited by this paper
• Disability weights for comorbidity and their influence on Health-adjusted Life Expectancy

  2006cited by this paper
• Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

  2006cited by this paper
• The alcohol clamp: applications, challenges, and new directions--an RSA 2004 symposium summary.

  2006cited by this paper
• The Effect of Olanzapine on Craving and Alcohol Consumption

  2006cited by this paper
• The Brain's Dark Energy

  2006cited by this paper
• Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.

  2006cited by this paper
• Compassionate Cities: Public Health and End-of-Life Care

  2006cited by this paper
• A double-blind placebo-controlled study of the effects of naltrexone on alcohol sensitivity and genetic moderators of medication response

  2006cited by this paper
• Neurobiological Mechanisms of the Placebo Effect

  2005cited by this paper
• Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism?

  2005cited by this paper
• Toward a philosophical structure for psychiatry.

  2005cited by this paper
• Translational research in central nervous system drug discovery

  2005cited by this paper
• Challenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry.

  2005cited by this paper
• Effect of pattern and number of chronic ethanol exposures on subsequent voluntary ethanol intake in C57BL/6J mice

  2005cited by this paper
• Development of medications for alcohol use disorders: recent advances and ongoing challenges

  2005influential reference
• Actual causes of death in the United States, 2000.

  2004cited by this paper
• Increased ethanol drinking after repeated chronic ethanol exposure and withdrawal experience in C57BL/6 mice.

  2004cited by this paper
• Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis.

  2004cited by this paper
• Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking

  2004cited by this paper
• Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

  2004cited by this paper
• Challenge and Opportunity on the Critical Path to New Medical Products

  2004cited by this paper
• A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans.

  2004cited by this paper
• The 12-Month Prevalence and Trends in DSM–IV Alcohol Abuse and Dependence

  2004cited by this paper
• Research to practice: adoption of naltrexone in alcoholism treatment.

  2003cited by this paper
• A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients

  2003cited by this paper
• NPI-031G (puerarin) reduces anxiogenic effects of alcohol withdrawal or benzodiazepine inverse or 5-HT2C agonists.

  2003cited by this paper
• Understanding US addiction physicians' low rate of naltrexone prescription.

  2003cited by this paper

• Cigarette smoke exposure worsens the severity of alcoholic liver disease by increasing CYP pathway signaling in mice

  2026cites this paper
• Suvorexant for alcohol use disorder and post-traumatic stress disorder: study protocol for a phase II randomized clinical trial

  2026cites this paper
• Nalmefene and naltrexone reduce alcohol intake via selective efficacy in subpopulations distinguished by behavioral and blood-based biomarkers

  2026cites this paper
• Pharmacological interventions for alcohol use disorder: novel insights from recent clinical trials

  2026cites this paper
• DRD1 gene is associated with craving changes during withdrawal among patients with alcohol use disorder.

  2025cites this paper
• TNFR1 and TNFR2 levels in patients with severe alcohol use disorder undergoing withdrawal and their relationship with delirium tremens.

  2025cites this paper
• Precision Medicine in Substance Use Disorders: Integrating Behavioral, Environmental, and Biological Insights.

  2025cites this paper
• Advancing medication development for alcohol use disorder: A narrative review integrating preclinical, human laboratory, and clinical trials.

  2025cites this paper
• The use of baclofen to reduce alcohol-attributable hospitalizations and emergency department admissions.

  2025cites this paper
• Leveraging meta-regression to test if medication effects on cue-induced craving are associated with clinical efficacy

  2024cites this paper
• Medication Development For Aud: A Systematic Review Of Clinical Trial Methodology.

  2024cites this paper
• AUD in perspective.

  2024cites this paper
• Sodium oxybate: A comprehensive review of efficacy and safety in the treatment of alcohol withdrawal syndrome and alcohol dependence.

  2024cites this paper
• The combination of donepezil and cognitive training for improving treatment outcomes for alcohol use disorder: Design of a randomized controlled trial.

  2024cites this paper
• Whole person recovery from substance use disorder: a call for research examining a dynamic behavioral ecological model of contexts supportive of recovery

  2024cites this paper
• Pharmacological Treatments for Alcohol Use Disorder: Considering the Role of Sex and Gender

  2024cites this paper
• Repurposing drugs for treatment of alcohol use disorder.

  2024cites this paper
• Testing pharmacotherapies for alcohol use disorder with cue exposure paradigms: A systematic review and quantitative synthesis of human laboratory trial methodology.

  2023cites this paper
• A practice quit model to test early efficacy of medications for alcohol use disorder in a randomized clinical trial

  2023cites this paper
• Beyond mediators: A critical review and methodological path forward for studying mechanisms in alcohol use treatment research.

  2023cites this paper
• Are medication effects on subjective response to alcohol and cue-induced craving associated? A meta regression study

  2023cites this paper
• Initial Validation of a Behavioral Phenotyping Model for Substance Use Disorder

  2023cites this paper
• Comorbid alcohol use disorder and post-traumatic stress disorder: A proof-of-concept randomized placebo-controlled trial with buprenorphine and naltrexone combination treatment.

  2023cites this paper
• Catechol-O-Methyltransferase inhibition and alcohol use disorder: Evaluating the efficacy of tolcapone in ethanol-dependent rats.

  2023cites this paper
• Structured tracking of alcohol reinforcement (STAR) for basic and translational alcohol research

  2023influential citation
• Using naltrexone to validate a human laboratory test system to screen new medications for alcoholism (TESMA)- a randomized clinical trial

  2023cites this paper
• Tiaprida, una alternativa de tratamiento en el trastorno por uso de alcohol: a propósito de un caso

  2023cites this paper
• The effect of neuroimmune modulation on subjective response to alcohol in the natural environment.

  2022cites this paper
• Perspectives on the pharmacological management of alcohol use disorder: Are the approved medications effective?

  2022cites this paper
• Tiapride, una alternativa de tratamiento para el trastorno por el uso de alcohol: a propósito de un caso

  2022cites this paper
• A Meta-Regression of Trial Features Predicting the Effects of Alcohol Use Disorder Pharmacotherapies on Drinking Outcomes in Randomized Clinical Trials: A Secondary Data Analysis.

  2022cites this paper
• Precision medicine in alcohol use disorder: Mapping etiologic and maintenance mechanisms to mechanisms of behavior change to improve patient outcomes.

  2022cites this paper
• Using machine learning to predict heavy drinking during outpatient alcohol treatment.

  2022cites this paper
• Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial

  2021cites this paper
• A meta-regression of methodological features predicting the effects of pharmacotherapies on subjective response to alcohol.

  2021cites this paper
• Mapping Data-Driven Individualized Neurobehavioral Phenotypes in Heavy Alcohol Drinkers.

  2021cites this paper
• Exploring regulation and function of dopamine D3 receptors in alcohol use disorder. A PET [11C]-(+)-PHNO study

  2021cites this paper
• Replikationskrise in der präklinischen Suchtforschung und Vorschläge zur Krisenbewältigung

  2021cites this paper
• Andrographis paniculata and Its Main Bioactive Ingredient Andrographolide Decrease Alcohol Drinking and Seeking in Rats Through Activation of Nuclear PPARγ Pathway.

  2021cites this paper
• The pharmacological understandings of alcohol use and misuse

  2021cites this paper
• Ibudilast moderates the effect of mood on alcohol craving during stress exposure.

  2021cites this paper
• Ibudilast attenuates alcohol cue-elicited frontostriatal functional connectivity in alcohol use disorder.

  2021cites this paper
• Ionic liquid [C3mim]OTf aqueous solution: Green high efficiency electroreduction for carbon dioxide at room-temperature

  2021cites this paper
• Increase in Plasma CCL11 (Eotaxin-1) in Patients with Alcohol Dependence and Changes During Detoxification.

  2021cites this paper
• Identification of Dihydromyricetin and Metabolites in Serum and Brain Associated with Acute Anti-Ethanol Intoxicating Effects in Mice

  2021cites this paper
• Baseline severity and the prediction of placebo response in clinical trials for alcohol dependence: A meta‐regression analysis to develop an enrichment strategy

  2021cites this paper
• Investigations on the influence of cue reactivity on relapse behavior in alcohol use disorder using innovative methods of statistical survival analysis

  2021cites this paper
• Integrative data analysis of self-efficacy in four clinical trials for alcohol use disorder.

  2021cites this paper
• An LC-MS/MS method for comparing the stability of ethanol's non-oxidative metabolites in dried blood spots during 90 days.

  2020cites this paper
• Influence of n-acetylcysteine maintenance on the pharmacodynamic effects of oral ethanol

  2020cites this paper
• Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial

  2020cites this paper
• Examining the Relationship Between Self-Reported Drinking and In-Laboratory Drinking and Craving: Is There Concordance?

  2020cites this paper
• Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline.

  2020cites this paper
• Differences in Sociodemographic and Alcohol-Related Clinical Characteristics Between Treatment Seekers and Nontreatment Seekers and Their Role in Predicting Outcomes in the COMBINE Study of Alcohol Use Disorder.

  2020cites this paper
• Systematic Review and Meta-Analysis of the Moderating Effect of rs1799971 in OPRM1, the Mu-opioid Receptor Gene, on Response to Naltrexone Treatment of Alcohol Use Disorder.

  2020cites this paper
• The future of translational research on alcohol use disorder

  2020cites this paper
• Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA

  2020cites this paper
• A novel human laboratory model for screening medications for alcohol use disorder

  2020influential citation
• Do behavioral pharmacology findings predict clinical trial outcomes? A proof-of-concept in medication development for alcohol use disorder

  2020cites this paper
• Probenecid Reduces Alcohol Drinking in Rodents. Is Pannexin1 a Novel Therapeutic Target for Alcohol Use Disorder?

  2019cites this paper
• Advancing Precision Medicine for Alcohol Use Disorder: Replication and Extension of Reward Drinking as a Predictor of Naltrexone Response

  2019cites this paper
• Developing neuroscience-based treatments for alcohol addiction: A matter of choice?

  2019cites this paper
• The Human Laboratory and Drug Development in Alcohol Use Disorder: Recent Updates.

  2019cites this paper
• Promoting activity of (α4)3(β2)2 nicotinic cholinergic receptors reduces ethanol consumption

  2019cites this paper
• Mobile alcohol biosensors and pharmacotherapy development research.

  2019cites this paper
• Dopamine and opioid systems adaptation in alcoholism revisited: Convergent evidence from positron emission tomography and postmortem studies.

  2019cites this paper
• Effect of suvorexant on event-related oscillations and EEG sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal

  2019cites this paper
• Diagnosis and Management of Alcohol Use Disorder in Patients with Liver Disease: Lights and Shadows

  2019cites this paper
• State-of-the-Art Treatment of Alcohol Use Disorder

  2019cites this paper
• Caenorhabditis elegans as a model system to identify therapeutics for alcohol use disorders

  2019cites this paper
• Alcohol and Pain: A Translational Review of Preclinical and Clinical Findings to Inform Future Treatment Strategies.

  2019cites this paper
• Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice.

  2019cites this paper
• Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review

  2019cites this paper
• Naltrexone effects on subjective responses to alcohol in the human laboratory: A systematic review and meta‐analysis

  2019cites this paper
• Glial gene networks associated with alcohol dependence

  2019cites this paper
• Interoception and alcohol addiction: Vagotomy induces long‐lasting suppression of relapse‐type behavior

  2019cites this paper
• Downregulation of M-channels in lateral habenula mediates hyperalgesia during alcohol withdrawal in rats

  2019cites this paper
• Alcohol and Opioid Use, Co‐Use, and Chronic Pain in the Context of the Opioid Epidemic: A Critical Review

  2018cites this paper
• Activation of amylin receptors attenuates alcohol‐mediated behaviours in rodents

  2018cites this paper
• Mining the nucleus accumbens proteome for novel targets of alcohol self-administration in male C57BL/6J mice

  2018cites this paper
• State-of-the-art behavioral and pharmacological treatments for alcohol use disorder

  2018cites this paper
• Investigational drugs for alcohol use disorders: a review of preclinical data

  2018cites this paper
• Efficacy and safety of sodium oxybate in alcohol‐dependent patients with a very high drinking risk level

  2018cites this paper
• Vasopressin and alcohol: a multifaceted relationship

  2018cites this paper
• Medication Development: Reducing Casualties in the Valley of Death and Providing Support for Survivors.

  2018cites this paper
• State-ofthe-art behavioral and pharmacological treatments for alcohol use disorder

  2018cites this paper
• Overcoming the “Valley of Death” in Medications Development for Alcohol Use Disorder

  2018cites this paper
• Opioid addiction, diversion, and abuse in chronic and cancer pain

  2018cites this paper
• Title Overcoming the " Valley of Death " in Medications Development for Alcohol Use Disorder

  2018cites this paper
• Ketogenic Diet Suppresses Alcohol Withdrawal Syndrome in Rats

  2018cites this paper
• Jobelyn suppresses hippocampal neuronal apoptosis and necrosis in experimental alcohol-induced brain stress.

  2018cites this paper
• Nicotine‐Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence

  2018cites this paper
• Substance use disorders and self- and other-directed violence among adults: Results from the National Survey on Drug Use And Health.

  2018cites this paper
• Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial

  2017cites this paper
• Oxytocin Reduces Alcohol Cue-Reactivity in Alcohol-Dependent Rats and Humans

  2017cites this paper
• Altered neural oscillations and elevated dopamine levels in the reward pathway during alcohol relapse

  2017cites this paper
• Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse (Part 2).

  2017cites this paper
• Reduced expression of purinergic P2X4 receptors increases voluntary ethanol intake in C57BL/6J mice.

  2017cites this paper
• The ABCD Study of Neurodevelopment: Identifying Neurocircuit Targets for Prevention and Treatment of Adolescent Substance Abuse

  2017cites this paper
• Pre-Clinical Studies with D-Penicillamine as a Novel Pharmacological Strategy to Treat Alcoholism: Updated Evidences

  2017cites this paper